Bayer on track to meet restructuring goals in 2024 first quarter

14 May 2024
bayer_big

Diversified German drugmaker Bayer (BAYN: DE) has reported group sales of 13.8 billion euros ($14.9 billion) for the first quarter of 2024, a fall of around 0.6%, meeting expectations.

The firm’s pharmaceuticals business posted higher sales and earnings, with an increase of 3.9% to 4.4 billion euros, supported by strong performances for Nubeqa (darolutamide), a cancer drug, and Kerendia (finerenone), a kidney disease med.

Core earnings per share fell 4.4% to 2.82 euros, while net income stood at 2 billion euros for the quarter.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical